Synthesize peer-reviewed science, every global clinical trial, and the full patent literature into one evidence layer, then find the white space where the science is open and the need is high.
ASCO, AACR, ESMO, ASH, DDW and more, One Zyme reads each abstract, poster, and presentation and turns it into structured data you can filter by drug, target, indication, phase, conference, or date.
Pharma and biotech conference presentations, structured for search.
One Zyme reads full-text literature, resolves it to the right targets, mechanisms, and assets, and distills consensus, conflict, and emerging hypotheses, with every claim traceable to its source.
One Zyme normalizes registries worldwide, including China, into one structured landscape, so you can see where programs are concentrating, what's reading out, and where activity is thin.
Every registry worldwide, normalized into one structured, searchable landscape.
| Trial ID | Title | Registry | Phase | Indication |
|---|---|---|---|---|
| ChiCTR2600126800 | Risk factors for poor wound healing after artificial-liver catheter removal | ChiCTR | N/A | Liver failure |
| ChiCTR2600126801 | Transcutaneous electrical acupoint stimulation in acute pancreatitis | ChiCTR | N/A | Acute pancreatitis |
| ChiCTR2600126790 | INSURE vs LISA surfactant delivery in extremely preterm infants | ChiCTR | N/A | Neonatal RDS |
| NCT06914207 | Oral TYK2 inhibitor in moderate-to-severe ulcerative colitis | ClinicalTrials.gov | Phase II | Ulcerative colitis |
| 2026-501883-42 | IL-23 antagonist maintenance therapy in Crohn's disease | EUCTR | Phase III | Crohn's disease |
One Zyme clusters the global patent corpus by mechanism and approach, revealing where IP is dense, where it's thinning, and where the genuine white space is forming. While One Zyme doesn't provide legal advice, it can give you an exceptionally deep analytical breakdown of patents and patent families.
One Zyme plots every approach by competitive density and unmet need at once. The opportunity isn't just the empty space, it's the empty space where patients still have no good option.
Cluster the literature, trials, and patent corpus by mechanism to expose where the science is open and competition is thin.
Score each indication on burden of disease, remission rates, treatment-failure populations, and durability gaps, grounded in cited evidence.
Pressure-test each opportunity against addressable population, pricing and reimbursement precedent, competitive intensity, and the shifting standard of care.
Rank approaches by the intersection of open white space, high unmet need, and attractive market dynamics, the opportunities worth a program, not just a paper.
Every R&D workflow runs on the same agents, data, and evidence trail that power the rest of the platform.
Explore Models & Data →Get a strategic briefing tailored to your therapeutic areas, target mechanisms, and pipeline priorities.
